TM2 domain containing 1 (TM2D1)

TM2 domain containing 1 is a beta-amyloid peptide-binding protein sharing structural similarity to seven-transmembrane domain G protein-coupled receptors, although its functional coupling to G proteins is not established[1][2][5]. It is implicated in mediating neuronal apoptosis in response to amyloid-beta, making it relevant to Alzheimer’s disease pathology[1][6][7]. The encoded protein has multiple transcript variants, and its expression correlates with regions vulnerable to neurodegeneration[1][3][7]. Major functional annotations include amyloid-beta binding and a role in cell death signaling, specifically apoptosis[1][4][7]. Diseases associated with TM2 domain containing 1 include Alzheimer’s disease and Mast syndrome[1][6]. There are no approved drugs specifically targeting TM2 domain containing 1 at present[1][6][7].

Other names

TM2D1Beta-amyloid peptide-binding proteinTM2 domain-containing protein 1TM2D1_HUMAN (UniProt designation)

Potential mechanism is modulation of amyloid-beta-induced apoptosis via binding interactions, possibly affecting β-amyloid aggregation or toxicity. No direct drug mechanisms are described in available sources.